CIK 0001396814 · Large accelerated filer
Pacira BioSciences, Inc.
Sign in to watch- Ticker
- PCRX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 510619477
- Phone
- 650-242-8052
- Business address
- 2000 SIERRA POINT PARKWAY, SUITE 900, BRISBANE, CA, 94005
- Former names
- Pacira Pharmaceuticals, Inc., PACIRA INC, Blue Acquisition Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $288,539
- in 2 filings, $289K under 10b5-1 plans
Net −$288,539. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-12-10 | Cross Shawn Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −9,104 | 175,000 | ||
| 2025-12-09 | Cross Shawn Chief Financial Officer | Option exercise 10b5-1 | +15,896 | $16.45 | $261K | 72,146 |
| 2025-12-09 | Cross Shawn Chief Financial Officer | Sale 10b5-1 | −15,896 | $25.03 | $398K | 56,250 |
| 2025-12-09 | Cross Shawn Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −15,896 | 184,104 | ||
| 2025-11-17 | SLONIN JONATHAN Chief Medical Officer | Sale 10b5-1 | −3,960 | $24.09 | $95K | 178,367.01 |
| 2025-11-10 | Cross Shawn Chief Financial Officer | Sale 10b5-1 | −12,060 | $22.09 | $266K | 56,250 |
| 2025-10-31 | Cross Shawn Chief Financial Officer | Shares withheld for taxes | −6,690 | $21.38 | $143K | 68,310 |
| 2025-09-04 | Ceesay Abraham Director | Sale 10b5-1 | −2,354 | $27.19 | $64K | 9,039 |
| 2025-08-07 | BIGAL MARCELO Director | Sale | −4,912 | $23.67 | $116K | 11,393 |
| 2025-08-01 | SLONIN JONATHAN Chief Medical Officer | Shares withheld for taxes | −315 | $22.07 | $7K | 182,327.01 |
| 2025-06-11 | Kronenfeld Mark A. Director | Grant or award | +6,163 | 31,065 | ||
| 2025-06-11 | Kronenfeld Mark A. Director | Grant or award | +9,999 | 34,901 | ||
| 2025-06-11 | Kronenfeld Mark A. Director | Grant or award · Stock Option (Right to Buy) | +11,279 | 11,279 | ||
| 2025-06-11 | Ceesay Abraham Director | Grant or award | +6,163 | 11,393 | ||
| 2025-06-11 | Ceesay Abraham Director | Grant or award · Stock Option (Right to Buy) | +11,279 | 11,279 | ||
| 2025-06-11 | Froimson Mark Director | Grant or award | +6,163 | 20,636 | ||
| 2025-06-11 | Froimson Mark Director | Grant or award · Stock Option (Right to Buy) | +11,279 | 11,279 | ||
| 2025-06-11 | BIGAL MARCELO Director | Grant or award | +6,163 | 16,305 | ||
| 2025-06-11 | BIGAL MARCELO Director | Grant or award · Stock Option (Right to Buy) | +11,279 | 11,279 | ||
| 2025-06-11 | YANG MICHAEL J. Director | Grant or award | +6,163 | 13,393 |
Page 4 of 9 · 161 trades